24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Licensing
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:53
Google, Amazon and Intel stumble as investors begin to question the price of the AI boom
12:53
Every student deserves a personal tutor, inside the classroom, too.
09:51
AI companies say their models are the best. Here's how to tell if that's true
08:35
What if the AI runs out of electricity?
More stories
Buzz
Most popular
Daily
Weekly
1
Cyber startup Cyera eyes $20 billion valuation in new funding talks
2
"A gorgeous situation": ServiceNow's CEO celebrates a shrinking workforce
3
Stealth Israeli cyber startup valued at over $1.5 billion recruits former 8200 chief
4
Intel’s $600 million question: How the Kiryat Gat explosion hit its forecast
5
Nikesh Arora's pay falls 19.5% to $80 million as Palo Alto Networks board lowers cap on stock awards
More news
Licensing
4 stories about Licensing
Israeli roads off-limits to Tesla Cybertruck due to licensing issues
18.07.24
|
Tomer Hadar
Ministry of Transportation holds back approval over bulletproof concerns
“Licensing practices are tilting the market in favor of certain providers against others”
07.05.22
|
James Spiro
Francisco Mingorance, Executive General at CISPE, explains how cloud monopolies are affecting licensing agreements online
Israel to Set Up Fast Track for Licensing Fintech Projects
19.08.19
|
Meir Orbach
According to the Israeli Ministry of Finance, there are currently 2,000 different entities awaiting licensing, many of which are fintech and blockchain companies that need to make only slight adjustments to comply with current regulations
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026